Tech Company Financing Transactions
Enhanced Genomics Funding Round
On 9/17/2025, Enhanced Genomics landed $19 million in Series A funding from BGF Ventures, Meltwind Advisory and ParkWalk Advisors.
Transaction Overview
Company Name
Announced On
9/17/2025
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to expand Enhanced's internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
St John's Innovation Park, Cowley Rd
Cambridge, CB4 0DS
UK
Cambridge, CB4 0DS
UK
Phone
Website
Email Address
Overview
We are the only biotechnology therapeutics discovery and development company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential. Unlocking decades worth of genetic data and providing unparalleled validation via our proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, we are able to expedite drug discovery and precision medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dietrich Stephan
Browse more venture capital transactions:
Prev: 9/17/2025: TeachMe.To venture capital transaction
Next: 9/17/2025: AIRIA venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs